Penumbra Inc. has announced its financial results for the third quarter of 2026, showcasing a strong performance that underscores the company's growth in the medical instruments sector. The results are particularly noteworthy as they come amid a pending acquisition by Boston Scientific Corporation.

For the third quarter ended September 30, 2026, Penumbra reported revenue of $410.1 million, marking a 15.6% increase compared to the same period in 2025. This growth reflects the company's strong position in the surgical and medical instruments and apparatus industry, specifically in thrombectomy solutions.

Company Overview

Penumbra Inc. (NYSE: PEN) is a leading company in the surgical and medical instruments and apparatus sector, classified under SIC code 3841. Based in Alameda, California, Penumbra specializes in innovative medical technologies aimed at treating challenging conditions such as ischemic stroke and venous thromboembolism. The company has been active in the market with several recent filings, including an 8-K on October 29, 2026, detailing its Q3 financial results.

What the Filing Says

The filing reveals key financial metrics for the quarter. Notable highlights include:

  • Global thrombectomy revenue reached $279.2 million, an 18.1% increase year-over-year.
  • U.S. VTE revenue surged by 26.0% compared to the previous year.
  • Gross profit margin improved to 68.3%, up 0.5% from Q3 2025.
  • Operating expenses totaled $229.6 million, which included $7.1 million in acquisition-related costs.
  • Net income for the quarter was reported at $42.3 million.

Impact

This financial update may affect various stakeholders, including investors, healthcare providers, and competitors in the surgical and medical instruments industry. With the pending acquisition by Boston Scientific, there is a heightened interest in how Penumbra's performance will influence the merger and the future direction of both companies.

What's Next

The filing does not specify what happens next regarding the acquisition or future financial guidance. However, the absence of a financial outlook for the full year 2026 suggests that the company is focused on navigating the acquisition process.

In summary, Penumbra's strong financial performance in Q3 2026 highlights its growth trajectory in the medical instruments sector, even as it prepares for a significant transition with the Boston Scientific acquisition.